A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients with Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR - Regional Cancer Care Associates LLC

Clinical Trials

A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients with Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR

Type of Cancer
Leukemia
Locations
Hackensack
Sponsor
Stemline Therapeutics
Protocol Number
STML-401-0214
Cancer Diagnosis
To Learn More Call
201-510-0910